A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction

被引：0
|
作者：
Kei Hosoda
Mizutomo Azuma
Chikatoshi Katada
Kenji Ishido
Masahiro Niihara
Hideki Ushiku
Mikiko Sakuraya
Marie Washio
Takuya Wada
Akinori Watanabe
Hiroki Harada
Satoshi Tanabe
Wasaburo Koizumi
Keishi Yamashita
Naoki Hiki
机构：
[1] Kitasato University School of Medicine,Department of Upper Gastrointestinal Surgery
[2] Kitasato University School of Medicine,Department of Gastroenterology
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Locally advanced esophagogastric junction cancer; Docetaxel; Oxaliplatin; S-1; Neoadjuvant chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1090 / 1097
页数：7
相关论文
共 50 条
  • [1] A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction
    Hosoda, Kei
    Azuma, Mizutomo
    Katada, Chikatoshi
    Ishido, Kenji
    Niihara, Masahiro
    Ushiku, Hideki
    Sakuraya, Mikiko
    Washio, Marie
    Wada, Takuya
    Watanabe, Akinori
    Harada, Hiroki
    Tanabe, Satoshi
    Koizumi, Wasaburo
    Yamashita, Keishi
    Hiki, Naoki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (06) : 1090 - 1097
  • [2] A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction
    Hosoda, K.
    Azuma, M.
    Katada, C.
    Ishido, K.
    Niihara, M.
    Ushiku, H.
    Sakuraya, M.
    Washio, M.
    Wada, T.
    Watanabe, A.
    Harada, H.
    Tanabe, S.
    Koizumi, W.
    Yamashita, K.
    Hiki, N.
    Watanabe, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] Neoadjuvant docetaxel, oxaliplatin and S-1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction
    Saito, Takuro
    Kurokawa, Yukinori
    Takahashi, Tsuyoshi
    Yamamoto, Kazuyoshi
    Yamashita, Kotaro
    Tanaka, Koji
    Makino, Tomoki
    Nakajima, Kiyokazu
    Eguchi, Hidetoshi
    Doki, Yuichiro
    GASTRIC CANCER, 2022, 25 (05) : 966 - 972
  • [4] Neoadjuvant docetaxel, oxaliplatin and S‑1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction
    Takuro Saito
    Yukinori Kurokawa
    Tsuyoshi Takahashi
    Kazuyoshi Yamamoto
    Kotaro Yamashita
    Koji Tanaka
    Tomoki Makino
    Kiyokazu Nakajima
    Hidetoshi Eguchi
    Yuichiro Doki
    Gastric Cancer, 2022, 25 : 966 - 972
  • [5] Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601
    Masaaki Iwatsuki
    Hiroyuki Orita
    Kazuma Kobayashi
    Shigekazu Hidaka
    Takaaki Arigami
    Tetsuya Kusumoto
    Hironaga Satake
    Eiji Oki
    Satoshi Tsutsumi
    Kazutoshi Tobimatsu
    Mototsugu Shimokawa
    Hiroshi Saeki
    Akitaka Makiyama
    Hideo Baba
    Masaki Mori
    Gastric Cancer, 2022, 25 : 180 - 187
  • [6] Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601
    Iwatsuki, Masaaki
    Orita, Hiroyuki
    Kobayashi, Kazuma
    Hidaka, Shigekazu
    Arigami, Takaaki
    Kusumoto, Tetsuya
    Satake, Hironaga
    Oki, Eiji
    Tsutsumi, Satoshi
    Tobimatsu, Kazutoshi
    Shimokawa, Mototsugu
    Saeki, Hiroshi
    Makiyama, Akitaka
    Baba, Hideo
    Mori, Masaki
    GASTRIC CANCER, 2022, 25 (01) : 180 - 187
  • [7] A phase I/II clinical trial of preoperative docetaxel/oxaliplatin/S-1 (DOS) combination therapy for esophagogastric junction adenocarcinoma.
    Kumagai, Koshi
    Hosoda, Kei
    Niihara, Masahiro
    Katada, Chikatoshi
    Ishido, Kenji
    Watanabe, Akinori
    Wada, Takuya
    Sakuraya, Mikiko
    Washio, Marie
    Higuchi, Tadashi
    Chuman, Motohiro
    Harada, Hiroki
    Yamashita, Keishi
    Kusano, Chika
    Hiki, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 429 - 429
  • [8] A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma
    Park, Inkeun
    Ryu, Min-Hee
    Choi, Yoon Hee
    Kang, Hyo Jeong
    Yook, Jeong Hwan
    Park, Young Soo
    Kim, Hyun Jin
    Jung, Hwoon-Yong
    Lee, Gin Hyug
    Kim, Kab Choong
    Kim, Byung Sik
    Kang, Yoon-Koo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (04) : 815 - 823
  • [9] A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma
    Inkeun Park
    Min-Hee Ryu
    Yoon Hee Choi
    Hyo Jeong Kang
    Jeong Hwan Yook
    Young Soo Park
    Hyun Jin Kim
    Hwoon-Yong Jung
    Gin Hyug Lee
    Kab Choong Kim
    Byung Sik Kim
    Yoon-Koo Kang
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 815 - 823
  • [10] Phase I study of docetaxel, oxaliplatin and S-1 (DOS) for patients with advanced gastric cancer
    Zang, D.
    Yang, D.
    Lee, H.
    Lee, B.
    Hwang, S.
    Kim, H.
    Song, H.
    Jung, J.
    Kim, J.
    Kwon, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 276 - 276
12345